In this Insights, we provide our perspective on rational treatment planning for patients with metastatic melanoma. Treatment planning should be individualized. Considerations include the extent and location of metastatic disease, tempo of disease progression, performance status, comorbidities with attention to underlying autoimmune disorders, and need for chronic immunosuppression and availability of clinical trials. Whenever possible, complete eradication of all metastatic disease should be the goal. Patients should be screened by history, physical examination, serum lactate dehydrogenase level, tumor BRAF mutation status, and complete body imaging, including central nervous system assessment. The Figure summarizes our current approach.
Kaufman HL, Margolin K, Sullivan R. Management of Metastatic Melanoma in 2018. JAMA Oncol. 2018;4(6):857–858. doi:10.1001/jamaoncol.2018.0170
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: